Adicet Bio (ACET) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic pipeline prioritization

• Announced a shift to focus ADI-001 development on autoimmune diseases, closing enrollment for the MCL study and sharing favorable top-line data from that cohort.

• Pipeline leverages gamma delta 1 T cells for both autoimmune and cancer indications, with a broad and differentiated approach.

• Emphasized years of research optimizing gamma delta 1 T cells for disease targeting and safety.

ADI-001 program insights

• ADI-001 shows exposure and B-cell depletion in blood comparable to autologous CAR-T therapies, with 23 of 24 patients achieving complete CD19 B-cell depletion.

• Demonstrates strong tissue trafficking, crucial for durable responses in autoimmune diseases.

• Lower risk of severe CRS and ICANS due to reduced IL-6 peaks compared to alpha beta T cells.

• Off-the-shelf nature minimizes risk of T-cell malignancies and supports community-based dosing.

Clinical data and development plans

• MCL cohort (n=10) showed 80% overall response rate, 60% CR rate, and 17.5 months median response duration, supporting shift to autoimmune focus.

• Initial autoimmune indications: systemic lupus, lupus nephritis, systemic sclerosis, and ANCA vasculitis, with INDs cleared and site activation underway.

• Clinical trial design includes three arms, single-dose ADI-001, and primary safety endpoints; first data expected in H1 next year.